Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network (Q70944303)
Jump to navigation
Jump to search
scientific article published on 01 September 1995
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network |
scientific article published on 01 September 1995 |
Statements
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network (English)
G J Gorse
R B Belshe
G B Patel
1 September 1995